A Novel GLP-1/FGF21 Dual Agonist ZT003 Has Therapeutic Potential for Obesity, Diabetes, and Nonalcoholic Steatohepatitis

被引：0
|
作者：
Zhang, Yuanyuan
Zhang, Yuying
Zhao, Chunlai
Lin, Simei
Guo, Wei
Wu, Bo
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-297-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
297-OR
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Exploring the therapeutic potential of Glucagon/GLP-1 dual agonist ZP2929 in a mouse model of diet induced and biopsy-confirmed non-alcoholic steatohepatitis
    Skarbaliene, J.
    Madsen, A. N.
    Mouritzen, U.
    Bak, H. H.
    Just, R.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S102 - S102
  • [32] PB-718, a Dual GLP-1/Glucagon Receptor Agonist Demonstrates Superior Weight-Loss Effect and Ameliorates Nonalcoholic Steatohepatitis (NASH) in Animal Models
    Lu, Wei
    Wang, Chunmei
    Luo, Xiaosu
    Zhang, Yinghui
    Hong, Liang
    Xu, Michael
    DIABETES, 2017, 66 : A50 - A50
  • [33] Safety, Pharmacokinetics, and Pharmacodynamics of the Novel Dual GLP-1/Glucagon Agonist SAR425899 in Healthy Subjects and Diabetes Patients
    Tillner, Joachim
    Posch, Maximillian G.
    Hueser, Andreas
    Teichert, Lenore
    Einig, Christine
    Bergmann, Karin
    Keil, Stefanie
    Rimbault, Mathieu
    Larsen, Philip Just
    Lorenz, Martin
    DIABETES, 2016, 65 : A6 - A7
  • [34] A single ascending dose study of the novel GLP-1 receptor agonist GL0034 (utreglutide) in individuals with obesity without diabetes
    Thennati, R.
    Burade, V.
    Natarajan, M.
    Shahi, P.
    Nagaraja, R.
    Panchal, S.
    Agrawal, S.
    Jandrain, B.
    Duvauchelle, T.
    Garcia-Ocana, A.
    Rutter, G. A.
    Pratley, R. E.
    Thorens, B.
    Vilsboll, T.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S320 - S321
  • [35] Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes
    Nowak, Mariusz
    Nowak, Wojciech
    Grzeszczak, Wladyslaw
    ENDOKRYNOLOGIA POLSKA, 2022, 73 (04) : 745 - 755
  • [36] Novel peptidic dual GLP-1/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound
    Ding, W-X
    Wang, H-Y
    Peng, L-J
    Zhang, F.
    Yuan, S.
    Zhao, L-H
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (23) : 12423 - 12436
  • [37] YH25724, a novel long-acting GLP-1/FGF21 dual agonist lowers both non-alcoholic fatty liver disease activity score and fibrosis stage in a diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis
    Hong, H. N.
    Kim, J. H.
    Choi, H. H.
    Kim, D.
    Kim, T. W.
    Tolbol, K. S.
    Feigh, M.
    Illemann, M.
    Rigbolt, K.
    Vrang, N.
    Kim, J. G.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S16 - S17
  • [38] The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes
    Coskun, Tamer
    Moyers, Julie S.
    Roell, William C.
    O'Farrell, Libbey
    Regmi, Ajit
    Ruan, Xiaoping
    Showalter, Aaron D.
    Sloop, Kyle
    Wainscott, David B.
    Willard, Francis S.
    Ficorilli, James V.
    Cabrera, Over
    Urva, Shweta
    Cooper, Fariba Norouziyan
    Guo, Lili
    Alsina-Fernandez, Jorge
    Qu, Hongchang
    DIABETES, 2021, 70
  • [39] The novel GIP, GLP-1, and glucagon triple receptor agonist LY3437943 exhibits robust efficacy in preclinical models of obesity and diabetes
    Coskun, T.
    Moyers, J. S.
    Roell, W.
    O'Farrell, L.
    Regmi, A.
    Showalter, A. D.
    Sloop, K. W.
    Wainscott, D. B.
    Willard, F. S.
    Ficorilli, J.
    Cabrera, O.
    Urva, S.
    Cooper, F. Norouziyan
    Alsina-Fernandez, J.
    Qu, H.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 116 - 116
  • [40] Potential of insulin deprescription adding a GLP-1 receptor agonist as a therapeutic strategy to improve the metabolic profiles of patients with type 2 diabetes mellitus
    Pozo, Victor Perez de Arenaza
    Salas, Jersy Cardenas
    Martinez, Clotilde Vazquez
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2024, 71 (09): : 405 - 407
12345